



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/017,577	12/14/2001	Vicki S. Thompson	LIT-PI-372	8146

7590 10/20/2004
Stephen R. Christian
Bechtel BWXT Idaho, LLC
P.O. Box 1625
Idaho Falls, ID 83415-3899

EXAMINER

COOK, LISA V

ART UNIT	PAPER NUMBER
----------	--------------

1641

DATE MAILED: 10/20/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/017,577	Applicant(s) THOMPSON ET AL.	
	Examiner Lisa V. Cook	Art Unit 1641	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 03 August 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 61-100 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 61-100 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Amendment Entry

1. Applicants response to the Restriction Requirement mailed 29 June 2004 is acknowledged. In the amendment filed therein claims 1-60 were canceled. New claims 61-100 were added. Accordingly the Restriction Requirement mailed 6/29/04 is MOOT. The new claims have been considered and the following Restriction Requirement is deemed appropriate.

Election/Restriction

2. Restriction to one of the following inventions is required under 35 U.S.C. 121
 - A. Claims 61-74 are drawn to a method for detecting a selected drug in a biological sample comprising specific antibodies and identifying a source of the biological sample via an antibody-enzyme conjugate, classified in class 435, subclass 7.1 for example.
 - B. Claims 75-88 are drawn to method for analyzing biological materials comprising individual specific antibodies, classified in class 435, subclass 7.9 for example.
 - C. Claims 89-100 are drawn to a solid support array comprising multiple antigens attached to a solid support, classified in class 422, subclass 57 for example.
3. The inventions are distinct, each from the other because of the following reasons:

Art Unit: 1641

Inventions **A** and **B** are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have distinct modes of operation. The method of invention A requires an antibody-enzyme conjugate (claim 61) to not only detect a selected drug, but also identify the source of the biological sample.

The method of invention B merely analyzes a biological sample by covalent bounding (claim 75) of formed immune complexes. No antibody-enzyme conjugate is required in the method of invention B. Accordingly the method of invention B is not limited to only antibody-enzyme conjugate reagents. The methods have diverse reagents (different effects), diverse method steps (different modes of operation), and measure diverse events (different functions). Thus restriction is proper.

Inventions **C** and **(A-B)** are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the array of invention C can be utilized in either of the materially different processes of invention A or invention B.

Art Unit: 1641

It is recognized that although the search for the inventions may overlap they are not totally co-extensive, where the search for one would fully encompass the search for the others. Because these inventions are distinct for the reasons given above and the search required for Inventions A-B are not mutually inclusive (i.e. the search for one invention is not required for the other inventions) restriction for examination purposes as indicated is proper.

4. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. Please note that the classifications in the restriction are illustrative only and **do not** represent all the classes and subclasses which must be searched for each invention; nor is the search limited to issued US patents, but rather includes foreign patents and applications as well as literature searches.

ELECTION OF SPECIES

5. This application contains claims directed to the following patentably distinct species of the claimed invention: The invention of Groups A and B include a plurality of disclosed patentably distinct inventions (various drugs, biological sample types, multiple antigens, solid supports, enzymes). Therefore, each disclosed patentably distinct component or embodiment is considered a separate invention.

Art Unit: 1641

6. Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits by selecting a single distinct embodiment I-IV to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1, 43-53, and 60 are generic.

As to invention A above: one of the following claims must be selected in each group:

I. With respect to the "multiple antigens" either one of claims 66-69 must be elected.

III. With respect to the "antibody conjugation" either one of claims 72 or 73 must be elected.

As to invention B above: one of the following claims must be selected in each group:

III. With respect to the "detection of the immune complexes" either one of claims 79/80, 81, 82, or 83 must be elected.

As to invention C above: one of the following claims must be selected in each group:

IV. With respect to the "multiple antigens" either one of claims 92/93, 94, 95, 96, or 97 must be elected.

7. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Art Unit: 1641

8. Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).
9. Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.
10. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143).
11. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Art Unit: 1641

12. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO fax center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1641 Fax number is (703) 872-9306, which is able to receive transmissions 24 hours/day, 7 days/week.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa V. Cook whose telephone number is (571) 272-0816. The examiner can normally be reached on Monday - Friday from 7:00 AM - 4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached on (571) 272-0823.

Any inquiry of a general nature or relating to the status of this application should be directed to Group TC 1600 whose telephone number is (571) 272-1600.




Lisa V. Cook

Patent Examiner

Remsen 3C-59

571-272-0818

10/5/04



LONG V. LE
SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

10/15/04